BR112015010980A2 - composição de excipientes e formas farmacêuticas de libertação prolongada com aumento de biodisponibilidade de drogas antibacterianas, drogas anticoccidianas e outros medicamentos para aves e suínos comerciais - Google Patents

composição de excipientes e formas farmacêuticas de libertação prolongada com aumento de biodisponibilidade de drogas antibacterianas, drogas anticoccidianas e outros medicamentos para aves e suínos comerciais

Info

Publication number
BR112015010980A2
BR112015010980A2 BR112015010980A BR112015010980A BR112015010980A2 BR 112015010980 A2 BR112015010980 A2 BR 112015010980A2 BR 112015010980 A BR112015010980 A BR 112015010980A BR 112015010980 A BR112015010980 A BR 112015010980A BR 112015010980 A2 BR112015010980 A2 BR 112015010980A2
Authority
BR
Brazil
Prior art keywords
drugs
composition
pharmaceutical forms
poultry
pigs
Prior art date
Application number
BR112015010980A
Other languages
English (en)
Other versions
BR112015010980A8 (pt
Inventor
Salvador Sumano López Héctor
Gutierrez Olvera Lilia
Original Assignee
Univ Mexico Nac Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nac Autonoma filed Critical Univ Mexico Nac Autonoma
Publication of BR112015010980A2 publication Critical patent/BR112015010980A2/pt
Publication of BR112015010980A8 publication Critical patent/BR112015010980A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Abstract

resumo “composição de excipientes e formas farmacêuticas de libertação prolongada com aumento de biodisponibilidade de drogas antibacterianas, drogas anticoccidianas e outros medicamentos para aves e suínos comerciais” a invenção refere-se a uma composição de excipientes e as formas farmacêuticas de libertação sustentada e aumento da biodisponibilidade de drogas para aves e porcos e a um método para a produção da mesma, compreendendo a referida composição: agentes farmaceuticamente ativos, agentes de promoção de biodisponibilidade, os polímeros para uso prolongado da droga libertada, agentes corantes e agentes aromatizantes. a composição de excipientes e as formas farmacêuticas da presente invenção otimizam a dosagem da droga e geram estirpes resistentes de bactérias através da otimização da relação entre a farmacocinética/farmacodinâmica de drogas. a composição possui diferentes formas e tamanhos que permitem que o produto seja identificado e seja aceito mais facilmente pelas aves ou suínos.
BR112015010980A 2012-11-14 2013-11-14 composição de veículos e formas farmacêuticas de liberação prolongada e aumento de biodisponibilidade de antibacterianos, anticoccidianos e outros fármacos em aves comerciais e porcos BR112015010980A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2012013222A MX347401B (es) 2012-11-14 2012-11-14 Composicion de vehiculos y formas farmaceuticas de liberacion sostenida y aumento de biodisponibilidad de antibacterianos, anticoccidianos y otros farmacos en aves comericales y cerdos.
PCT/MX2013/000137 WO2014077666A1 (es) 2012-11-14 2013-11-14 Composición de vehículos y formas farmacéuticas de liberación sostenida y aumento de biodisponibilidad de antibacterianos, anticoccidianos y otros fármacos en aves comerciales y cerdos

Publications (2)

Publication Number Publication Date
BR112015010980A2 true BR112015010980A2 (pt) 2017-07-11
BR112015010980A8 BR112015010980A8 (pt) 2019-10-01

Family

ID=50731496

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010980A BR112015010980A8 (pt) 2012-11-14 2013-11-14 composição de veículos e formas farmacêuticas de liberação prolongada e aumento de biodisponibilidade de antibacterianos, anticoccidianos e outros fármacos em aves comerciais e porcos

Country Status (7)

Country Link
US (1) US20160279063A1 (pt)
CN (1) CN105050599A (pt)
BR (1) BR112015010980A8 (pt)
DO (1) DOP2015000111A (pt)
MX (1) MX347401B (pt)
SV (1) SV2015004970A (pt)
WO (1) WO2014077666A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127429A (zh) * 2014-07-28 2014-11-05 邳州正康生物技术有限公司 一种用于防治畜禽呼吸道疾病的饮水剂及其制备方法
CN105878228B (zh) * 2016-06-27 2018-05-18 河北天元药业有限公司 一种延胡索酸泰妙菌素可溶性粉及其制备方法
AU2018351640B2 (en) * 2017-10-20 2024-02-29 Axichem Ab Synthetic capsaicin analogues as bioenhancers
CN107648616A (zh) * 2017-10-27 2018-02-02 四川康四海动物药业有限公司 一种替米考星包合工艺
CN108484693B (zh) * 2018-03-14 2020-08-11 中科荣信（苏州）生物科技有限公司 一种壳寡糖-抗生素偶联物及其制备方法和应用
CN108324694A (zh) * 2018-04-13 2018-07-27 成都乾坤动物药业股份有限公司 一种土霉素缓释片及其制备方法与用途
CN108379593A (zh) * 2018-05-28 2018-08-10 青岛科技大学 一种制备氟苯尼考-壳聚糖/长链羧酸纳米胶束冻干粉的方法
CN109700783A (zh) * 2019-03-04 2019-05-03 江西派尼生物药业有限公司 一种壳聚糖包被替米考星微球的制备方法
CN114533679B (zh) * 2022-01-28 2023-03-14 马超锋 一种磺胺氯哒嗪缓释纳米胶粒及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06321810A (ja) * 1992-09-24 1994-11-22 Bayer Kk 鶏の筋胃破砕力を利用した持効性製剤
GB9500863D0 (en) * 1995-01-17 1995-03-08 Grampian Pharm Ltd Medicated animal foodstuffs
DE10328666A1 (de) * 2003-06-26 2005-01-13 Bayer Healthcare Ag Tabletten enthaltend Geschmacks-und/oder Aromastoffe
US20080260892A1 (en) * 2005-07-15 2008-10-23 Fisher Feeds Limited Animal Feed
CN1969851A (zh) * 2005-11-25 2007-05-30 天津市润拓生物技术有限公司 一种畜禽使用的恩诺沙星结肠靶向丸剂制备方法
US20070209599A1 (en) * 2006-03-10 2007-09-13 Archer-Daniels-Midland Company Methods and compositions for increased productivity in animals
WO2008030469A2 (en) * 2006-09-07 2008-03-13 Merial Limited Soft chewable, tablet, and long-acting injectable veterinary antibiotic formulations
CN101744772A (zh) * 2008-11-27 2010-06-23 河南农业大学 一种制备兽用药物缓释微粒的方法
CN102648896A (zh) * 2011-02-28 2012-08-29 郑州福源动物药业有限公司 一种畜禽使用的恩诺沙星缓释微丸及其制备方法

Also Published As

Publication number Publication date
MX347401B (es) 2017-04-18
MX2012013222A (es) 2014-05-22
WO2014077666A1 (es) 2014-05-22
CN105050599A (zh) 2015-11-11
US20160279063A1 (en) 2016-09-29
DOP2015000111A (es) 2015-11-15
SV2015004970A (es) 2017-07-10
BR112015010980A8 (pt) 2019-10-01

Similar Documents

Publication Publication Date Title
BR112015010980A2 (pt) composição de excipientes e formas farmacêuticas de libertação prolongada com aumento de biodisponibilidade de drogas antibacterianas, drogas anticoccidianas e outros medicamentos para aves e suínos comerciais
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
BR112014027841A8 (pt) Derivado de pirazola e o uso do mesmo para fins médicos
BR112015018168A2 (pt) inibidores de rock suaves
EA201792591A1 (ru) Фармацевтические препараты
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
BR112017022846A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de dois fármacos de partículas diferentes
PE20160183A1 (es) FORMULACION DE LIBERACION MODIFICADA DEL ACIDO (-)-(3aR,4S,7aR)-4-HIDROXI-4m-TOLILETINIL-OCTAHIDRO-INDOL-1-CARBOXILICO (AFQ056)
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
EA201070625A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
CO6180495A2 (es) Formulacion de medicamento liquida
BR112017022856A2 (pt) combinação de dose fixa inviolável que proporciona rápida liberação de duas drogas a partir de partículas
ECSP15033649A (es) Un medicamento combinado que comprende fenilefrina y paracetamol
BR112017022335A2 (pt) combinação de dose fixa inviolável que fornece rápida liberação de dois fármacos a partir de partículas e matriz
UY37518A (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
BR112017000468A2 (pt) forma de dosagem de cápsula de liberação prolongada
BR112015010650A2 (pt) composição contendo somente levonorgestrel melhorada para contracepção oral otimizada com conteúdo definido de levonorgestrel, regime de dosagem e preparo farmacêutico
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
BR112017022855A2 (pt) combinação de dose fixa inviolável que provê liberação rápida de dois fármacos a partir de partículas e um pó
BR112014001751A2 (pt) derivados de pirazolina e seu uso como moduladores seletivos do receptor de estrogênio
ECSP17008187A (es) Formas de dosificación farmacéutica
BR112018072583A2 (pt) composição farmacêutica de comprimido em comprimido estável
EA202193041A1 (ru) Многослойные фармацевтические или нутрицевтические твердые лекарственные формы, содержащие производные пиримидина и/или пурина и витамины в, их получение и применение

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL